Cipla launches rapid antigen detection CIPtest for COVID-19 diagnosis
Rapid antigen detection test directly detects presence or absence of coronavirus antigen in patient s body, generating results in 15-20 minutes; ICMR-approved CIPtest is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent
BusinessToday.In | December 16, 2020 | Updated 14:46 IST
Cipla s extensive distribution network will help in ensuring supply of kits across country
After Elifast ELISA test kit, drug major Cipla has said it ll partner with Premier Medical Corporation Private Limited to produce rapid antigen COVID-19 testing kits in India. While Premier Medical Corporation Private will make the kits, Cipla will be responsible for marketing and distribution of the rapid antigen detection test kit that s used for the detection of coronavirus antigen. The testing kit will be marketed under the brand name CIPtest .